Page 4 - Target Rwe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Target rwe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Target Rwe Today - Breaking & Trending Today

Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting

/PRNewswire/ Target RWE, a leading real-world evidence (RWE) solutions company for the healthcare industry, shared results from a recent TARGET-NASH study. ....

A Sidney Barritt , Phepatology Communications , Division Of Gastroenterology , University Of North Carolina At Chapel Hill , Associate Professor , North Carolina , Patient Determinants , Histologic Diagnosis , Real World , Target Rwe ,

Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission

/PRNewswire/ Real-world evidence leader Target RWE announced today COVID-19 data that has been recently published in the peer-reviewed medical journal. ....

United States , Julie Mallory Crawford , Elizabeth Verna , Hepatology Research , Columbia University Transplant Clinical Research Center , Clinical Research , Columbia University Division Of Digestive , Columbia University Division , Senior Director , Medical Affairs , Clinical Infectious Diseases , Patient Characteristics , With Coronavirus Disease , Hospitalized Across , Target Rwe , ஒன்றுபட்டது மாநிலங்களில் , ஹெபடாலஜி ஆராய்ச்சி , மருத்துவ ஆராய்ச்சி , கொலம்பியா பல்கலைக்கழகம் பிரிவு , மூத்தவர் இயக்குனர் , மருத்துவ வாழ்க்கைத்தொழில்கள் , மருத்துவ தொற்று நோய்கள் , நோயாளி பண்புகள் , இலக்கு றுவே ,

Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population

Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population
Poster of Distinction Award Granted to TARGET-IBD Research
News provided by
Share this article
Share this article
DURHAM, N.C., May 23, 2021 /PRNewswire/ Research presented today at Digestive Disease Week (DDW) 2021 evaluated the prevalence and predictors of immunomodulator use as concomitant therapy with two commonly prescribed biologics, vedolizumab (Entyvio) or ustekinumab (Stelara), in patients with inflammatory bowel disease (IBD). Data from Target RWE s TARGET-IBD large longitudinal cohort
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort was selected for the Poster of Distinction Award. ....

Megan Lutz , Public Health , Prnewswire Research , University Of Wisconsin School Medicine , Digestive Disease Week , Commonly Used , Concomitant Therapy , World Cohort , Wisconsin School , More Likely , Achieve Mucosal Healing , Biologic Experienced Patients , Target Rwe , மேகன் லூட்ஸ் , பொது ஆரோக்கியம் , பல்கலைக்கழகம் ஆஃப் விஸ்கான்சின் பள்ளி மருந்து , செரிமான நோய் வாரம் , பொதுவாக பயன்படுத்தப்பட்டது , விஸ்கான்சின் பள்ளி , மேலும் வாய்ப்பு , உயிரியல் அனுபவம் வாய்ந்த நோயாளிகள் , இலக்கு றுவே ,

TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy

Patient Determinants for Histologic Diagnosis of Nonalcoholic Fatty Liver Disease in the Real World: A TARGET-NASH Study, aimed to determine patient characteristics that are predictive of having a diagnosis by biopsy versus a diagnosis using clinical criteria.
Analyzing 3,474 participants with NAFLD from August 2016 to March 2019, the study found 67% had not had a liver biopsy.
Analyzing 3,474 adult participants with nonalcoholic fatty liver disease (NAFLD) managed in usual clinical practice from August 2016 to March 2019, the study found 67% of the cohort had not had a liver biopsy. Predictive factors of having a diagnosis by biopsy included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). Overall, median age was 59 years, 59% were female, 75% White, and 66% obese. The most common comorbid conditions included cardiovascular disease (19%), osteoarthritis (10%), and mental health diagnoses or depression (49%). Of note, patients who had progres ....

A Sidney Barritt , Tarun Sanyal , Dan Gagnier Jeffrey Mathews , Department Of Internal Medicine , Division Of Gastroenterology , University Of North Carolina At Chapel Hill , Virginia Commonwealth University , Gagnier Communications , Associate Professor , North Carolina , Chapel Hill , Internal Medicine , Target Rwe , அருண் சன்யால் , துறை ஆஃப் உள் மருந்து , பிரிவு ஆஃப் இரைப்பை குடல் , பல்கலைக்கழகம் ஆஃப் வடக்கு கரோலினா இல் தேவாலயம் மலை , வர்ஜீனியா காமன்வெல்த் பல்கலைக்கழகம் , இணை ப்ரொஃபெஸர் , வடக்கு கரோலினா , தேவாலயம் மலை , உள் மருந்து , இலக்கு றுவே ,